LOTTE Biologics

Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to contribute to a healthier world through innovative therapies. 

At the Syracuse Bio Campus in New York, it offers high-quality GMP manufacturing services for drug substances, with a total capacity of 40,000L supported by eight 5,000L stainless steel bioreactors. The facility also includes extensive QC testing laboratories and warehouses approved by over 62 regulatory agencies globally. By early 2025, LOTTE BIOLOGICS will expand into Antibody-Drug Conjugates (ADCs) conjugation services, with over $80 million invested in ADC modalities, providing seamless end-to-end services from drug substance manufacturing to conjugation.

Looking toward 2030, LOTTE BIOLOGICS is constructing three bio plants in Songdo, South Korea. The first plant, expected to be operational by 2026, will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, as well as multiple 2,000L single-use bioreactors to meet clinical production needs. Collectively, these facilities will provide a manufacturing volume exceeding 360,000L in bioreactor capacity.